The Sidney Kimmel Comprehensive Cancer Center
- Country
- 🇺🇸United States
- Ownership
- Private, Subsidiary
- Employees
- -
- Market Cap
- -
Assessing the Acceptability of the Use of a Mobile Health App Among Young Adult Female Survivors of Childhood Cancer
- Conditions
- Childhood Cancer Survivor
- Interventions
- Other: Mobile Health App
- First Posted Date
- 2017-08-08
- Last Posted Date
- 2021-04-01
- Target Recruit Count
- 30
- Registration Number
- NCT03242200
- Locations
- 🇺🇸
Johns Hopkins Hospital, Baltimore, Maryland, United States
Neoadjuvant Immunoradiation for Resectable Non-Small Cell Lung Cancer
- Conditions
- Non-Small Cell Lung Cancer
- Interventions
- Radiation: Thoracic RadiationProcedure: lobectomyDrug: Standard of care adjuvant chemotherapy
- First Posted Date
- 2017-08-02
- Last Posted Date
- 2024-07-12
- Target Recruit Count
- 9
- Registration Number
- NCT03237377
- Locations
- 🇺🇸
Johns Hopkins Bayview Medical Center, Baltimore, Maryland, United States
🇨🇦Princess Margaret Cancer Centre, Toronto, Ontario, Canada
Neurocognitive Functioning With Genu-Sparing Whole Brain Radiation Therapy for Brain Metastases
- Conditions
- Brain Metastases
- Interventions
- Radiation: whole brain radiation therapy
- First Posted Date
- 2017-07-21
- Last Posted Date
- 2024-06-07
- Target Recruit Count
- 24
- Registration Number
- NCT03223922
- Locations
- 🇺🇸
The SKCCC at Johns Hopkins, Baltimore, Maryland, United States
🇺🇸Sibley Memorial Hospital, Washington, District of Columbia, United States
MEDI-551 as Maintenance Therapy After Allogeneic Stem Cell Transplant in Multiple Myeloma
- Conditions
- Multiple Myeloma
- Interventions
- Drug: MEDI-551 Maintenance
- First Posted Date
- 2017-07-14
- Last Posted Date
- 2019-01-14
- Target Recruit Count
- 1
- Registration Number
- NCT03218163
- Locations
- 🇺🇸
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States
HIF-2 Alpha Inhibitor PT2385 in Treating Patients With Recurrent Glioblastoma
- Conditions
- Recurrent Glioblastoma
- Interventions
- Drug: HIF-2alpha Inhibitor PT2385Other: Pharmacological StudyOther: Laboratory Biomarker AnalysisOther: Pharmacogenomic Study
- First Posted Date
- 2017-07-13
- Last Posted Date
- 2022-05-09
- Target Recruit Count
- 24
- Registration Number
- NCT03216499
- Locations
- 🇺🇸
Cleveland Clinic Taussig Cancer Center, Cleveland, Ohio, United States
🇺🇸UAB Comprehensive Cancer Center, Birmingham, Alabama, United States
🇺🇸Jonsson Comprehensive Cancer Center at UCLA, Los Angeles, California, United States
Study of CRS-207, Nivolumab, and Ipilimumab With or Without GVAX Pancreas Vaccine (With Cy) in Patients With Pancreatic Cancer
- Conditions
- Pancreatic Cancer
- Interventions
- First Posted Date
- 2017-06-16
- Last Posted Date
- 2024-08-07
- Target Recruit Count
- 61
- Registration Number
- NCT03190265
- Locations
- 🇺🇸
Johns Hopkins SKCCC, Baltimore, Maryland, United States
GVAX Pancreas Vaccine (With CY) in Combination With Nivolumab and SBRT for Patients With Borderline Resectable Pancreatic Cancer
- Conditions
- Pancreatic Cancer
- Interventions
- Radiation: Stereotactic Body Radiation (SBRT)
- First Posted Date
- 2017-05-19
- Last Posted Date
- 2025-02-03
- Target Recruit Count
- 31
- Registration Number
- NCT03161379
- Locations
- 🇺🇸
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States
🇺🇸Medical College of Wisconsin, Milwaukee, Wisconsin, United States
Pilot Study With CY, Pembrolizumab, GVAX, and IMC-CS4 (LY3022855) in Patients With Borderline Resectable Adenocarcinoma of the Pancreas
- Conditions
- Pancreatic Cancer
- Interventions
- First Posted Date
- 2017-05-15
- Last Posted Date
- 2025-01-09
- Target Recruit Count
- 11
- Registration Number
- NCT03153410
- Locations
- 🇺🇸
Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, United States
Idelalisib Post Allogeneic Hematopoietic Stem Cell Transplant (HSCT) in B Cell Derived Malignancies
- Conditions
- B Cells-TumorsMantle Cell LymphomaLarge B-Cell Diffuse Lymphoma of Bone (Diagnosis)B Cell Chronic Lymphocytic LeukemiaFollicular Lymphoma
- Interventions
- Drug: Placebo Oral Tablet
- First Posted Date
- 2017-05-12
- Last Posted Date
- 2024-03-12
- Target Recruit Count
- 16
- Registration Number
- NCT03151057
- Locations
- 🇺🇸
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States
A Study of Blinatumomab in Patients With Pre B-cell ALL and B-cell NHL as Post-allo-HSCT Remission Maintenance
- Conditions
- Acute Lymphoblastic LeukemiaB-cell Non Hodgkin LymphomaPre B-Cell Acute Lymphoblastic Leukaemia
- Interventions
- First Posted Date
- 2017-04-14
- Last Posted Date
- 2025-05-22
- Target Recruit Count
- 44
- Registration Number
- NCT03114865
- Locations
- 🇺🇸
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States